About this trial
On average, the dental condition of elderly people is poor due to various reasons. The importance of oral health maintenance of the ageing population has been recognized by the World Health Organization (WHO), as oral health plays a key role in reaching the global goal of the "Decade of Healthy Ageing 2021-2030".
New measures for maintaining good oral health are welcome. The use of antibacterial photodynamic therapy (aPDT) and antibacterial blue light (aBL) has been studied and found to reduce the amount of plaque in the mouth. The Lumoral device is a CE-marked home medical device combining aPDT and aBL, and it is effective in reducing the development of plaque and harmful bacteria in the plaque. The device has also been shown to be easy and safe to use. In this study, a combination of regular dental appointments with the importance of enhanced dental self-care, will be tested as one regional solution for reaching the global goal set by WHO.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
An elderly (age ≥ 65 years) person living at home or at care home, with a possibility to regular dental care appointments
Ability to understand and sign the informed consent
At least 10 teeth in the mouth, including implants
Ability to understand and follow the study protocol, including tooth brushing and following the instructions for the use of Lumoral Treatment, based on the assessment of the investigator
Disqualifiers
Uncontrolled diabetes mellitus (DM)
Severe dementia or other similar conditions that may restrict understanding of the study information and protocol
Presence of any physical limitation or restriction that might restrict Lumoral use
Active smoking and use of other tobacco products
Trial design
Parallel
Treatments tested in this trial
Lumoral Treatment
DeviceHome-use of photodynamic antibacterial dual-light device, used with a marker substance (indocyanine green)
Standard oral hygiene methods
BehavioralBest available standard oral self-care hygiene methods performed at home and instructed by oral healthcare professionals, supported by professional cleaning at the oral healthcare clinic
Treatment groups
Trial outcomes
Primary outcomes
Bleeding on probing (BOP)
Change in the inflammatory parameter BOP.A full-mouth assessment at six sites per tooth (mesiobuccal, buccal, distobuccal, mesiolingual, lingual, distolingual). Gingival bleeding is considered as positive if bleeding occurs within 15 seconds after gentle probing with a probe at the sulcus. Dichotomous scoring to each site of the tooth as bleeding "1 present" and "0 absent". BOP is reported as the percentage (%) of sites with positive findings. Calculation formula: number of bleeding sites/ 6 times number of teeth.
Secondary outcomes
Plaque index (RMNPI)
Assessment of six index teeth, measured at four sites per tooth * Dichotomous scoring to each site of the tooth as plaque "1 present" and "0 absent" * RMNPI reported as the percentage (%) of sites with plaque * Calculation formula: number of sites with plaque/ 4 times number of teeth
Periodontal Pocket Depth (PPD)
A full-mouth assessment, measured at six sites per tooth. Assessed from the base of the pocket to the gingival margin (mm)
Active matrix metalloproteinase 8 (aMMP-8)
Change in periodontal inflammation marker aMMP-8. The oral rinse fluid sample collection and the aMMP-8 marker analysis will be performed using Periosafe test (Dentognostics GmbH) according to the manufacturer's instructions.
Oral Bacterial flora
Quantification of periodontopathic bacteria by 16S rRNA sequencing analysis \- Microbiological samples can be collected using Iso Taper Paper Points, size-20 (VDW GmbH) from selected gingival/periodontal pockets with maximum initial probing depth. The paper points can be placed into sterile, small-aliquot containers, and immediately stored at -20°C until analysis
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Koite Health Oy
Lead sponsor
University of Helsinki
Collaborator